filgrastim Archives | Page 4 of 8

FDA accepts Tanvex’s BLA

by Bioblast Editor | Nov 28, 2018 | Biosimilars updates

Tanvex announces that the FDA has accepted its BLA for biosimilar filgrastim.

Zarxio® recognition

by Bioblast Editor | Nov 1, 2018 | Biosimilars updates

Sandoz’s biosimilar Zarxio® is included in Express Script’s 2018 National Preferred Formulary.

Alternative filgrastim products gain favour

by Bioblast Editor | Sep 10, 2018 | Biosimilars updates

Significant increase in the use of alternative filgrastim products reported among Medicare Part B beneficiaries.

Amgen’s suit against Apotex

by Bioblast Editor | Aug 7, 2018 | Biosimilars updates

Amgen files third suit against Apotex based on aBLAs for biosimilars of Neupogen® (filgrastim) and Neulasta® (pegfilgrastim). The patent under scrutiny, US Patent No. 9,856,287 was issued on 2 January this year and therefore was not included in earlier ‘patent...

First biosimilar filgrastim launched in South Africa

by Bioblast Editor | Jul 25, 2018 | Biosimilars updates

Teva launches first biosimilar filgrastim in South Africa at 70% of the price of Amgen’s product. This comes more than 5 years after Teva first sought regulatory approval, demonstrating the backlog of products awaiting approval from the South African Health...